Why Localized LLMs Matter in Pharma and Other Regulated Industries

What Localized Means: Four Controls You Either Own or Rent

“Localized LLM” is used loosely. Some people mean a model running on a server in the company’s own data center. Others mean an open-weight model running in a private cloud tenant. Others mean a hosted frontier model with processing restricted to the EU. These are different arrangements with different consequences, and a localized LLM pharma decision goes wrong most often when people use one word for all of them.

The European Medicines Agency’s guiding principles on large language models, published on 29 August 2024 for staff across the European medicines regulatory network, offer a useful starting classification. The document sorts LLM access into four groups: third-party models hosted externally and used through an online interface; third-party models hosted externally as part of an enterprise solution; third-party open-source models hosted internally; and models trained or retrained internally.¹ EMA notes that the way users interact with a model affects flexibility, control, resource requirements, and integration, and that these factors should be weighed when selecting a model type for a given line of work.¹

That classification is about who runs the model. For a regulated company, it helps to go one level further and ask which specific controls each arrangement gives you. We find four controls cover almost every concern that quality, privacy, legal, and IT leaders raise.

With those four controls in mind, the options form a spectrum rather than a choice between “cloud” and “on-prem.”

Read down the last two columns and the pattern is clear. Hosted offerings have moved a long way on location and access. They cannot, by their nature, give you ownership of the version or the timing of change, because the provider has to retire old models to make room for new ones. That is the core reason localized models matter in regulated work, and it is a different reason from the one most people give first.

A note on scope. The same four controls apply in banking, insurance, defense, and public-sector work, and much of this article would read the same for those sectors. We focus on pharma and biotech because that is where GxP validation, patient data, and partner confidentiality combine most tightly, and where we work.

Intellectual Property: Prompts Are a Disclosure Channel

A pharma company’s most valuable information is often not patented yet, or never will be. Process parameters, formulation know-how, impurity profiles, analytical methods, unpublished clinical results, and development strategy are protected mainly as trade secrets. Generative AI adds a new path for that information to leave the company: someone pastes it into a prompt.

Why Trade Secret Law Makes This a Governance Question

Trade secret protection depends on how the owner behaves. Under US federal law, information qualifies as a trade secret only if, among other conditions, “the owner thereof has taken reasonable measures to keep such information secret.”² The EU Trade Secrets Directive sets a parallel condition: the information must have been subject to reasonable steps, under the circumstances, by the person lawfully in control of it, to keep it secret.³

Neither law names AI tools. But “reasonable measures” is judged against what a careful company would do at the time. In 2026, a careful company knows its staff use LLMs daily. If a dispute ever turns on whether a process description was kept secret, the other side will ask what controls governed where employees could send it. A clear record that confidential technical content goes only to models inside a defined boundary is part of the answer.

EMA’s own staff guidance makes the same point for regulators. It tells users to check prompts to avoid inputting sensitive information including personal data, trade secrets, data protected by intellectual property law, and data where existing contracts restrict sharing.¹ It also states that “The potential for the prompts being stored and further processed presents risks in terms of confidential information, data protection and privacy.”¹

What Enterprise Hosted Terms Already Solve

It would be unfair to stop there. Enterprise terms from the large providers now address the most common worry, which is that your prompts will train a model other customers use. Microsoft’s documentation for models sold through Azure states that prompts, completions, embeddings, and training data are not available to other customers, not available to the model providers, and not used to train generative AI foundation models without the customer’s permission or instruction.⁴ Amazon Bedrock describes a model deployment account in each region, owned by the Bedrock service team, to which model providers have no access, so providers cannot see customer prompts and completions.⁵

For much of a company’s confidential material, those commitments, backed by a signed data processing agreement and a security review, are a reasonable measure. We would not tell a client that a well-contracted enterprise deployment is careless for internal policies, meeting summaries, or general drafting.

Where Localization Still Adds Something

Localization adds value for IP in three narrower situations:

• Partner and licensor restrictions. Co-development, licensing, and contract manufacturing agreements often restrict disclosure of the partner’s information to third parties. Many were written before AI processors existed and have no carve-out for them. Whether a cloud model provider counts as a permitted recipient is a contract question, and a model inside your own boundary avoids the question.
• Core process knowledge. For a small set of information (a commercial process, a platform method, a manufacturing recipe), leadership may decide that any third-party processing, however well contracted, is more exposure than it will accept. That is a legitimate risk appetite decision, and a local model is the way to give those teams AI help at all.
• Fine-tuned models. When you fine-tune a model on proprietary data, the resulting weights encode some of that data. The weights become an asset worth protecting in their own right. Holding them yourself keeps that asset inside the same controls as the source data.

Patient Data and GDPR: Where Processing Happens and Who Can Reach It

Pharma and biotech companies handle personal data across clinical development, pharmacovigilance, medical information, patient support programs, and real-world evidence work. Much of it is health or genetic data. Under GDPR, data concerning health, genetic data, and biometric data used for identification belong to the special categories in Article 9, which may be processed only under specific conditions.⁶ Chapter V then sets conditions for any transfer of personal data to a third country.⁶ In the United States, HIPAA can also apply where a company works with identifiable health information as, or on behalf of, a covered entity, for example in some patient support and real-world data programs.

The Transfer Question Is Broader Than Server Location

Many teams treat data residency as a question of where the servers are. European regulators treat it more broadly. The European Data Protection Board’s recommendations on supplementary measures for transfers, adopted in final form on 18 June 2021 after the Court of Justice’s Schrems II judgment, state that “remote access from a third country (for example in support situations) and/or storage in a cloud situated outside the EEA offered by a service provider, is also considered to be a transfer.”⁷ The same paragraph says that a company using international cloud infrastructure must assess whether and where its data will be transferred, unless the provider is established in the EEA and states clearly in its contract that the data will not be processed at all in third countries.⁷

For an LLM workload, that means the relevant questions are not only where inference runs. They include where logs are stored, where abuse monitoring data goes, where a support engineer is located when troubleshooting, and where a retrieval index is hosted.

The Legal Basis for EU to US Transfers Is Settled for Now, Not for Good

For transfers to certified US companies, the EU-US Data Privacy Framework currently provides a legal basis. On 3 September 2025, the EU General Court dismissed a challenge brought by French MP Philippe Latombe and upheld the framework.⁸ Latombe appealed to the Court of Justice on 31 October 2025.⁹ The two earlier transatlantic arrangements, Safe Harbor and Privacy Shield, were both struck down by that court, in 2015 and 2020.⁸ A pharma company whose AI architecture depends entirely on transfers to US processing has taken on a dependency on the outcome of that appeal. Region-bound or self-hosted processing for EU patient data removes the dependency.

What Region-Bound Hosted Options Now Offer

The hosted providers have responded to these concerns, and it is worth knowing exactly what they offer. Microsoft Foundry, for example, offers three processing options for its hosted models. Global deployment types may process data in any Azure region. Data Zone types process data only within a Microsoft-specified zone (US, EU, or Asia Pacific). Standard and regional provisioned types process prompts and responses within the customer-specified Azure geography.¹⁰ Data stored at rest remains in the designated geography for all types.¹⁰

Two details matter for a privacy review. First, the zones can change: Microsoft states that it “can add regions to either data zone without prior notice to improve capacity and availability.”¹⁰ Second, abuse monitoring is part of the data flow. Microsoft’s documentation explains that when its systems detect indicators of potential abuse, a sample of prompts and completions may be selected for review, first by automated means and then by human reviewers where needed. For deployments in the European Economic Area, those reviewers are located in the EEA, and approved customers can apply for modified abuse monitoring, which turns off the data storage and human review steps.⁴

These are real controls, and for many patient-data use cases a correctly configured region-bound deployment will satisfy the privacy team. The point is that “EU region” is a configuration with several settings, not a single checkbox, and someone has to verify each one.

Fine-Tuned Weights Can Carry Personal Data Obligations

There is one privacy issue where localization matters more than most teams expect. In December 2024, the EDPB adopted Opinion 28/2024 on data protection aspects of AI models. The Board’s position is that “AI models trained with personal data cannot, in all cases, be considered anonymous.”¹¹ Whether a given model is anonymous must be assessed case by case, and for it to count as anonymous, the likelihood of extracting personal data from it, directly or through queries, should be insignificant.¹¹

The practical consequence for pharma is direct. If you fine-tune a model on safety case narratives, patient support transcripts, or clinical notes, you should assume the resulting weights may themselves be personal data until an assessment shows otherwise. The weights then need the same residency, access, and retention controls as the training data. A model you host yourself, in a region you choose, makes that far easier to show than one whose fine-tuned copy lives in a provider’s service.

Controlled Data Boundaries: Mapping Every Place the Data Goes

A useful way to think about localization is as a data boundary: a defined set of systems, locations, and people inside which a given class of data may move freely, and outside which it may not go. The model is only one component inside that boundary. Most real exposures come from the components around it.

An LLM Application Has More Data Flows Than People Assume

OWASP’s 2025 list of top risks for LLM applications places sensitive information disclosure second, and describes the sensitive information at stake as including personal identifiable information, financial details, health records, confidential business data, security credentials, and legal documents.¹² NIST’s Generative AI Profile describes data privacy risks from leakage and unauthorized use, and notes that models may leak, generate, or correctly infer sensitive information about individuals.¹³ Neither risk is limited to the model provider. Both apply to every place the data passes through.

For any LLM use case, map these flows before deciding where the model runs:

Localization changes the answers for some rows and leaves others untouched. Running the model yourself removes the provider monitoring store and gives you direct control of the inference logs and weights. It does nothing about retrieval that ignores access rights, output stored in the wrong place, or an internal support engineer with broader access than needed.

The Internal Boundary Matters as Much as the External One

A localized model can create a new internal exposure. Consider a single company-wide assistant, running on your own hardware, with retrieval across clinical, regulatory, HR, and commercial repositories. It keeps everything inside the company. It can also show an unblinded efficacy table to someone on the blinded study team, or an HR investigation to a colleague of the person investigated, if retrieval does not enforce the permissions of the source systems.

In GxP and clinical settings, the internal boundary is often the stricter one. Blinding, firewalls between commercial and medical functions, and need-to-know access for safety data are not satisfied just because the data never left your network. A localized architecture should therefore be designed around several boundaries, each matched to a data class, rather than one large internal zone.

Validation Stability: Keeping the Model You Validated

This is the reason for localization that is most specific to regulated industries, and the one hosted offerings are least able to address. A computerized system used for GxP work is validated in a defined state. Changes to that state go through change control, with an impact assessment and, where needed, retesting. A model that changes, or disappears, on someone else’s schedule does not fit that process well.

Hosted Models Are Retired on the Provider’s Timeline

The major providers do offer pinned model snapshots, which do not change while they are available. The difficulty is how long they stay available. OpenAI’s published policy is at least six months’ notice before shutting down a generally available model, at least three months for specialized variants, and possibly much shorter notice, such as two weeks, for preview models.¹⁴ Its deprecations page lists a shutdown date of 23 October 2026 for the gpt-4o snapshot dated 13 May 2024, and records that gpt-4.5-preview was deprecated on 14 April 2025 and removed from the API on 14 July 2025.¹⁴

Cloud platforms that resell these models add their own lifecycle rules. On Amazon Bedrock, each model card states a date before which the model will not reach end of life, and a Legacy notice period of either six months or 45 days. During the Legacy period, existing customers “may lose access after 15 days of inactivity,” and after the end-of-life date the model is removed from all AWS Regions and “requests made to it will fail.”¹⁵ In Microsoft Foundry, a deployment set to a specific model version stays on that version until the retirement date, at which point it automatically upgrades to the current default version. A deployment set to “auto-update to default” upgrades within two weeks of a new default being designated. A deployment set to no automatic upgrade “stops working” once the retirement date is reached.¹⁶ Each option has a consequence for a validated system: an unplanned model change, a forced migration, or an outage.

Fine-tuning a hosted model does not avoid this. OpenAI states that inference on fine-tuned models is disabled when the underlying base model is deprecated,¹⁴ and Bedrock does not allow new fine-tuning jobs on a model once it enters its Legacy state.¹⁵ A hosted fine-tuned model lasts only as long as the base model it was built on, however much validation effort went into it.

Behavior Can Change Between Versions That Share a Name

A 2023 study from Stanford and UC Berkeley compared the March 2023 and June 2023 versions of GPT-3.5 and GPT-4 across tasks including math, code generation, and US medical licensing questions. GPT-4 identified prime versus composite numbers with 84% accuracy in the March version and 51% in the June version. The authors concluded that the behavior of the “same” LLM service “can change substantially in a relatively short amount of time.”¹⁷ Dated snapshots exist to prevent that kind of unannounced change for API users. But when a snapshot is retired, the replacement is by definition a different model, and the whole validation question returns.

Even a Fixed Model Is Not Automatically Repeatable

Owning the weights is necessary for stability but not sufficient. LLM output depends on the software that serves the model as well as the weights. The documentation for vLLM, an open-source inference server used to run open-weight models, states plainly: “vLLM does not guarantee the reproducibility of the results by default, for the sake of performance.” It offers settings that make results reproducible, including a batch invariance option that makes outputs insensitive to how the server schedules requests, and it adds that reproducibility holds only “on the same hardware and the same vLLM version.”¹⁸

That has two consequences. A self-hosted model can still vary from run to run unless it is configured for repeatability, and the hardware and server version belong in the validated configuration alongside the weights. On the other hand, when you control the serving stack, you can choose repeatability, trading some throughput for it. On a shared hosted service, that choice is not yours to make.

What Regulators Expect About Model Change

FDA’s January 2025 draft guidance on using AI to support regulatory decision-making for drugs and biological products is still a draft, and its scope is specific: it covers AI used to produce information supporting regulatory decisions about safety, effectiveness, or quality, and it excludes drug discovery and operational uses, such as drafting a submission, that do not affect patient safety, drug quality, or the reliability of study results.¹⁹ Within that scope, its section on life cycle maintenance is direct. It says that “sponsors should anticipate inherent, model-directed changes and the need to identify and evaluate those changes, as well as any intentional changes to the model over the drug product life cycle,” and that in manufacturing, changes that may affect AI model performance should be evaluated through the manufacturer’s change management system.¹⁹

That points back to ICH Q10, which says a change management system “should provide a high degree of assurance there are no unintended consequences of the change.”²⁰ It is hard to give that assurance about a change whose timing, content, and notice period are set by a vendor. It is much easier when the model version changes only because your own change control approved it.

The Honest Trade-Offs Against Hosted Frontier Models

None of the above means every regulated workload should move to a local model. The trade-offs are substantial, and a leadership team deciding on localization needs to see them plainly.

Capability

The largest hosted frontier models remain the most capable systems available for open-ended reasoning, long and complex documents, and tasks where the model must bring in broad knowledge. Open-weight models have closed much of the gap. Stanford’s 2025 AI Index reported that open-weight models reduced the performance difference with closed models from 8% to 1.7% on some benchmarks in a single year.²¹ But “some benchmarks” is the important qualifier. Benchmark averages hide differences on the hard, specialized tasks that matter most in regulatory and scientific work, and each new frontier release can reopen the gap for a time.

The practical answer is to test on your own tasks. Many pharma use cases are narrow: extracting fields from a document, classifying a complaint, checking a record against a template, summarizing a defined section. Narrow tasks are where smaller models perform best. A peer-reviewed study in npj Digital Medicine used a locally run open-weight model (Llama 2, in three sizes) to extract five clinical features from 500 patient medical histories, and found the 70 billion parameter version reached high sensitivity and specificity, for example 100% sensitivity and 96% specificity for detecting liver cirrhosis.²² The authors built the pipeline for local use specifically because cloud services require sending privileged information to remote servers.²²

Hardware and Infrastructure

Model size drives hardware needs, and simple arithmetic gives a first estimate. A model’s weights at 16-bit precision take about two bytes per parameter, so a 70 billion parameter model needs roughly 140 GB of GPU memory for the weights alone, before the memory used for long contexts and concurrent users. Quantized versions (lower numerical precision) reduce that substantially, at some risk to accuracy that should be tested for each task.

Recent open-weight releases are designed to run on less. When OpenAI released its gpt-oss models under the Apache 2.0 license in August 2025, it stated that the larger model runs on a single 80 GB GPU and the smaller one can run on devices with 16 GB of memory, and it named hosting on-premises for data security among the uses early partners were exploring.²³ These are the vendor’s own claims, and your throughput and latency needs will set the real hardware requirement. Still, the barrier to a first local deployment is lower than it was two years ago.

Maintenance and People

The larger burden is ongoing work, not purchase. Someone has to own model serving, capacity planning, monitoring, evaluation when a new model is considered, and the documentation a validated system requires. A hosted provider does much of this as part of its service. When you run the model, those tasks become yours, and they need named owners with the skills to do them. For a mid-size biotech, finding and keeping those people can be the deciding factor.

Security Patching

Running your own model means running your own inference software, and that software has vulnerabilities like any other. In 2024, Wiz researchers disclosed a remote code execution flaw in Ollama, a popular tool for running models locally. It was fixed in version 0.1.34 within days of disclosure. At the time, Wiz noted that “Ollama does not support authentication out-of-the-box,” and its internet scan found over 1,000 exposed instances.²⁴ The broader lesson from that disclosure is that tools in this space are often young and may lack standard security features such as authentication.²⁴

NIST’s Generative AI Profile makes the same point from the other direction: information security for AI systems includes protecting the integrity and confidentiality of code, training data, and model weights, and it expands the attack surface through risks such as prompt injection and data poisoning.¹³ A major hosted provider runs a large security program. When you self-host, you take on that responsibility, and your patch cadence for inference servers, drivers, and container images becomes part of your validated state.

Licensing

“Open weights” does not mean “no conditions.” The Llama 3.1 license, for example, requires compliance with Meta’s Acceptable Use Policy and requires companies whose products had more than 700 million monthly active users at the release date to request a separate license from Meta.²⁵ Other models use permissive licenses such as Apache 2.0.²³ Your legal team should review the specific license of any model before it enters a GxP or commercial workflow, and that review belongs in the system’s documentation.

Matching Use Cases to Deployment Positions

The right answer for most pharma and biotech companies is a portfolio: several deployment positions, each used for the work it fits. The decision for any single use case comes down to which of the four controls it requires, and the least burdensome position that provides them.

Start With the Data Class and the Validation Status

Two attributes of a use case settle most of the decision. The first is the most sensitive class of data the use case will touch, including anything retrieval might pull in. The second is whether the output feeds a GxP decision or record, which determines whether version and timing control are needed.

These are illustrations, not rules. A region-bound hosted model with a pinned snapshot can be the right choice for a GxP use case if the business accepts periodic revalidation as the price of higher capability. A local model can be right for low-risk work if the company already runs one and the task fits it. The table’s value is in making the reasoning explicit so that each choice is recorded and defensible.

A Five-Step Decision for Each Use Case

Keep the Application Portable

Whatever the mix, design applications so the model behind them can be swapped with limited rework. Keep prompts, retrieval logic, and evaluation sets separate from any single provider’s API specifics. Portability protects you in both directions: it lets you move a use case to a local model if a retirement notice arrives at a bad time, and it lets you move a use case to a hosted model if a local one falls behind on capability.

What to Put in Place Before a Local Model Goes Live

A localized model inherits every obligation of a validated computerized system, plus a few specific to AI. Companies that treat a first local model as an IT experiment often find, months later, that nobody can say exactly which version is running or who approved it. The following elements should exist before the first production use.

A Complete Configuration Baseline

Because output depends on more than the weights, the validated configuration has to describe the whole serving stack. At minimum, record:

• The model name, source, license, and a cryptographic hash of the weight files, so you can prove the file running today is the file you tested.
• Any quantization method and precision, since these change outputs.
• The inference server software and version, GPU driver version, and container image identifiers.
• Whether batch-invariant or other deterministic settings are enabled, and the sampling parameters used.
• The system prompt, prompt templates, and any output constraints, under version control.
• The retrieval index version and the document set it was built from, where retrieval is used.

Any change to an item on this list is a change to the validated system and goes through change control, scaled to risk.

An Evaluation Set That Outlives the Model

Build a task-specific evaluation set with expected results agreed by subject matter experts. Run it at validation, after every approved change, and on a periodic schedule. It is the evidence that the system still performs as validated, and it is what makes a later move to a better model fast rather than a new project.

Named Owners and a Patch Cadence

Assign an owner for the model service, an owner for its security, and a quality owner for its validated state. Agree how security patches to the inference stack will be assessed and applied. Most patches to serving software will not change model outputs, but some can, and the evaluation set is how you check.

Access Control and Logging Designed for the Data Class

Apply the permissions of source systems to retrieval, restrict who can read inference logs, and set log retention to match the data class rather than defaulting to “keep everything.” For patient data, bring the privacy team in before logging is designed, since full prompt logs of patient information are themselves a personal data store.

An Exit Plan

Decide in advance what happens when the local model is no longer good enough, when its license terms change, or when a better option appears. A local model gives you control over timing. It does not remove the need to plan for change, only the need to accept someone else’s schedule.

Conclusion

Localized LLMs matter in pharma and biotech for a specific set of reasons, and it pays to be precise about which ones apply. Hosted frontier models, configured well and contracted well, now answer many questions about where data is processed and who can reach it. They cannot give a regulated company ownership of the model version or the timing of change, and for long-lived GxP use cases that is often the deciding factor. Contract-restricted partner data, restricted process knowledge, and fine-tuned weights that may carry personal data obligations are the other places where a model inside your own boundary is worth the effort. Against those benefits sit real burdens: lower capability on open-ended work, hardware, ongoing operations, security patching, and license review. The companies that handle this well run a portfolio, match each use case to the least burdensome position that meets its requirements, and document why.

Sakara Digital works with pharma and biotech organizations deciding where each AI use case should run and what it takes to keep a validated AI system in its validated state. If you are weighing a localized LLM strategy and want an independent view on which of your use cases need it, and which do not, we are happy to have that conversation.

For Further Reading